Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Ovarian Neoplasms 5Melanoma 3Kidney Neoplasms 3Gliosarcoma 3Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Astrocytoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Precancerous Conditions 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Meningioma 1Medulloblastoma 1Lymphoma, Follicular 1

Interventions

Paclitaxel 7Pemetrexed 3Cisplatin 3Carboplatin 3pembrolizumab 2durvalumab 2adavosertib 2Trastuzumab 2Radiotherapy 2Nivolumab 2FANG vaccine 2Docetaxel 2CP protocol 2Brachytherapy 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1seribantumab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olaparib 1niraparib 1larotrectinib 1ipatasertib 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Uterine Neoplasms × FANG vaccine × Clear all
NCT03073525 2023-04-05

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Gradalis, Inc.

Phase 2 Completed
25 enrolled 15 charts
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT02725489 2021-01-27

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Mary Crowley Medical Research Center

Phase 2 Completed
13 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡